FEMY Femasys Inc.
USHealthcareAs of 2026-07-10 16:00
Why FEMY matters now
Femasys Inc. (FEMY) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.99 with +3.64% on the session and $12.0M in market capitalization; recent performance reads 1-month -43.65% and YTD -64.93%.
The latest financial table shown here is Q1 2026, with revenue of $424.9K, net income of $328.6K, and EPS of $0.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -152.3%.
The latest indexable market news headline is "Femasys Regains Compliance with Nasdaq Listing Requirements" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Canning John Charles filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.85
P/S
5.13
EV/EBITDA
-1.22
DCF Value
$-5.11
FCF Yield
-152.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
53.1%
Operating Margin
-687.9%
Net Margin
-521.8%
ROE
-258.1%
ROA
-75.2%
ROIC
-118.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $424.9K | $328.6K | $0.08 |
| Q4 2025 | $813.4K | $-4.0M | $-1.33 |
| FY 2025 | $2.3M | $-18.6M | $-9.40 |
| Q3 2025 | $729.4K | $-4.2M | $-2.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
-2.22
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.